These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39272200)

  • 1. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment.
    Desguerre I; Barrois R; Audic F; Barnerias C; Chabrol B; Davion JB; Durigneux J; Espil-Taris C; Gomez-Garcia de la Banda M; Guichard M; Isapof A; Nougues MC; Laugel V; Le Goff L; Mercier S; Pervillé A; Richelme C; Thibaud M; Sarret C; Schweitzer C; Testard H; Trommsdorff V; Vanhulle C; Walther-Louvier U; Altuzarra C; Chouchane M; Ropars J; Quijano-Roy S; Cances C
    Orphanet J Rare Dis; 2024 Sep; 19(1):344. PubMed ID: 39272200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
    Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
    J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
    Al-Zaidy SA; Kolb SJ; Lowes L; Alfano LN; Shell R; Church KR; Nagendran S; Sproule DM; Feltner DE; Wells C; Ogrinc F; Menier M; L'Italien J; Arnold WD; Kissel JT; Kaspar BK; Mendell JR
    J Neuromuscul Dis; 2019; 6(3):307-317. PubMed ID: 31381526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study.
    Barrois R; Griffon L; Barnerias C; Gitiaux C; Desguerre I; Fauroux B; Khirani S
    Sleep Med; 2024 Jul; 119():335-341. PubMed ID: 38749258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
    Thomsen G; Burghes AHM; Hsieh C; Do J; Chu BTT; Perry S; Barkho B; Kaufmann P; Sproule DM; Feltner DE; Chung WK; McGovern VL; Hevner RF; Conces M; Pierson CR; Scoto M; Muntoni F; Mendell JR; Foust KD
    Nat Med; 2021 Oct; 27(10):1701-1711. PubMed ID: 34608334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates.
    Mundada V; Narayan O; Arora S; Beri N; Abusamra R; Mullasery D; Parashar D
    Muscle Nerve; 2024 Oct; 70(4):808-815. PubMed ID: 39087519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
    Al-Zaidy S; Pickard AS; Kotha K; Alfano LN; Lowes L; Paul G; Church K; Lehman K; Sproule DM; Dabbous O; Maru B; Berry K; Arnold WD; Kissel JT; Mendell JR; Shell R
    Pediatr Pulmonol; 2019 Feb; 54(2):179-185. PubMed ID: 30548438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1.
    Finnegan R; Manzur A; Munot P; Dhawan A; Murugan A; Majumdar A; Wraige E; Gowda V; Vanegas M; Main M; O'Reilly E; Baranello G; Muntoni F; Scoto M
    Neuromuscul Disord; 2024 Sep; 42():22-26. PubMed ID: 39111255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy.
    Kirschner J; Bernert G; Butoianu N; De Waele L; Fattal-Valevski A; Haberlova J; Moreno T; Klein A; Kostera-Pruszczyk A; Mercuri E; Quijano-Roy S; Sejersen T; Tizzano EF; van der Pol WL; Wallace S; Zafeiriou D; Ziegler A; Muntoni F; Servais L
    Eur J Paediatr Neurol; 2024 Jul; 51():73-78. PubMed ID: 38878702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.
    Shell RD; McGrattan KE; Hurst-Davis R; Young SD; Baranello G; Lavrov A; O'Brien E; Wallach S; LaMarca N; Reyna SP; Darras BT
    Neuromuscul Disord; 2023 Aug; 33(8):670-676. PubMed ID: 37455203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
    Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
    Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.